• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neuraxis Inc.

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    SC 13G 1 rosalind_nrsx_13d_nov202.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    (Rule 13d-101)

    Under the Securities Exchange Act of 1934

    Neuraxis, Inc.

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    64134X201

    (CUSIP Number)

    11611 N. Meridian Street, Suite 330 Carmel, IN 46032

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    November 12, 2024

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


     

     

     

     

     

     

    CUSIP No. 64134X201

     

    13D

     

    Page 2 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)


    Rosalind Advisors, Inc.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)   ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
    0

     

    8.

     

    SHARED VOTING POWER

     

    2,100,840 shares of Common Stock issuable upon conversion of 2,100,840 preferred stock (see Item 5) 1

     

    9.

     

    SOLE DISPOSITIVE POWER
      0

     

    10.

     

    SHARED DISPOSITIVE POWER

     

    2,100,840 shares of Common Stock issuable upon conversion of 2,100,840 preferred stock (See Item 5)

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,100,840 shares of Common Stock issuable upon conversion of 2,100,840 preferred stock (See Item 5)   

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

     


    1 As more fully described in Item 5, the shares of Preferred Stock are subject to a 9.99% blocker, and the percentage set forth in row (13) gives effect to such blockers. However, as more fully described in Item 5, the securities reported in rows (8), (10) and (11) show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows (8), (10) and (11).


      

    CUSIP No. 64134X201

     

    13D

     

    Page 3 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Steven Salamon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER

     

    105,042 shares of Common Stock issuable upon conversion of 105,042 preferred stock (See Item 5) 1

     

     

    8.

     

    SHARED VOTING POWER


    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

    9.

     

    SOLE DISPOSITIVE POWER
     

    105,042 shares of Common Stock issuable upon conversion of 105,042 preferred stock (See Item 5) 1

     

    10.

     

    SHARED DISPOSITIVE POWER
     

    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)   ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     


      

    CUSIP No. 64134X201

     

    13D

     

    Page 4 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Gil Aharon

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     
    OO

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    ONTARIO, CANADA

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER


     105,042 shares of Common Stock issuable upon conversion of 105,042 preferred stock (See Item 5) 1

     

    8.

     

    SHARED VOTING POWER

    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

    9.

     

    SOLE DISPOSITIVE POWER


     105,042 shares of Common Stock issuable upon conversion of 105,042 preferred stock (See Item 5) 1

     

    10.

     

    SHARED DISPOSITIVE POWER
     
    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    IN

     

     


     

     

     

     

     

     

    CUSIP No. 64134X201

     

    13D

     

    Page 5 of 9 Pages

     

     

     

     

     

     

     

     

     

     

    1.

     

    NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    Rosalind Master Fund L.P.

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)    ¨
    (b)    ¨

     

     

    3.

     

    SEC USE ONLY
     

     

     

    4.

     

    SOURCE OF FUNDS (see instructions)
     

     

     

    5.

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     ¨

     

     

    6.

     

    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    CAYMAN ISLANDS

     

     

     

     

     

     

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

     

    7.

     

    SOLE VOTING POWER
    0

     

    8.

     

    SHARED VOTING POWER
     

    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

    9.

     

    SOLE DISPOSITIVE POWER
     
    0

     

    10.

     

    SHARED DISPOSITIVE POWER
     

    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

     

     

     

     

    11.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,890,756 shares of Common Stock issuable upon conversion of 1,890,756 preferred stock (See Item 5) 1

     

     

    12.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions)    ¨

     

     

    13.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.9%1

     

     

    14.

     

    TYPE OF REPORTING PERSON (see instructions)

    PN

     

     


     

     

     

     

     

     

     

    CUSIP No. 64134X201

     

    13D

     

    Page 7 of 9 Pages

     

     

     

     

     

     

    Item 1.  Security and Issuer.

     

    (a)

    This statement relates to the Preferred Stock (the “Shares”) of Neuraxis, Inc., a Delaware corporation (the "Company").

     

     

     

     

    (b)

    Address of Issuer’s Principal Executive Offices:
    11611 N. Meridian Street, Suite 330 Carmel, IN 46032.

     

     

     

     

     

    Item 2.  Identity and Background.

     

    (a)

    This statement is filed by:

    (i)Rosalind Advisors, Inc. (“Advisor” to RMF) 

    (ii)Rosalind Master Fund L.P. (“RMF”) 

    (iii)Steven Salamon (“President” and portfolio manager of the Advisor) 

    (iv)Gil Aharon (“Secretary” and portfolio manager of the Advisor) 

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Each of the Reporting Persons is party to that certain Joint Filing Agreement, as further described in Item 7. Accordingly, the Reporting Persons are hereby filing a joint Schedule 13D.

     

     

     

     

    (b)

    Address of the Principal Office or, if none, residence

    Rosalind Advisors, Inc.

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Rosalind Master Fund L.P.

    P.O. Box 309

    Ugland House, Grand Cayman

    KY1-1104, Cayman Islands

     

     

    Steven Salamon

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

    Gil Aharon

    15 Wellesley Street West

    Suite 326,

    Toronto, Ontario

    M4Y 0G7 Canada

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 64134X201

     

    13D

     

    Page 8 of 9 Pages

     

     

    (c)

    The principal business of Rosalind Advisors, Inc. is to operate as an investment advisory firm and to make public equity investments.

     

     

     

     

    (d)

    No Reporting Person has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

     

     

     

    (e)

    No Reporting Person has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

     

    (f)

    Mr. Salamon and Mr. Aharon are citizens of Canada, resident in Ontario

     

    Item 4.  Purpose of Transaction

    On November 19, 2024, the Board appointed Dr. Aharon to the Board, effective January 1, 2025.

    Item 5.  Interest in Securities of the Issuer.

     Amount beneficially owned:

    The information as of the date of the event which requires filing of this statement required by Items 5(a) – (c) is set forth in Rows 7 – 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 13 of the cover page for each Reporting Person is based on 6,980,227 shares of Common Stock issued and outstanding as of September 30, 2024, as represented in the Company’s Form 10-Q filed with the Securities and Exchange Commission on November 12, 2024, and assumes the conversion of the Company’s reported preferred stock (the “Reported Preferred Stock”), subject to the Blockers (as defined below).

    Pursuant to the terms of (i) the certificate of designations containing the terms of the Reported Preferred Stock, the Reporting Persons cannot convert the Reported Preferred Stock to the extent the Reporting Persons would beneficially own, after any such conversion, more than 9.99% of the outstanding shares of Common Stock (the "Preferred Stock Blockers"). Consequently, as of the date of the event which requires the filing of this statement, the Reporting Persons were not able to exercise all of the Reported Preferred Stock due to the Blockers.

    Rosalind Advisors, Inc. is the investment advisor to RMF and may be deemed to be the beneficial owner of shares held by RMF.  Steven Salamon and Gil Aharon are the portfolio managers of the Advisor and may be deemed to be the beneficial owner of shares of Preferred Stock held by RMF.  Notwithstanding the foregoing, the Advisor, Mr. Salamon and Mr Aharon disclaim beneficial ownership of any such shares.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

     

     

     

     

    Item 7.  Material to Be Filed as Exhibits.

     

     

     

     

     

    A Joint Filing Agreement by and among Rosalind Advisors, Inc. Rosalind Master Fund L.P., and Steven Salamon, was originally filed on November 27, 2024, as an Exhibit.


     

    CUSIP No. 64134X201

     

    13D

     

    Page 9 of 9 Pages

     

     

     

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    ROSALIND

     

    Steven Salamon

    Signature

     

    Steven Salamon/President, Rosalind Advisors, Inc.

    Name/Title

     

    11/27/2024

    Date

     

     

    Exhibit A

    Joint Filing Agreement

     

    The undersigned hereby agree that this Statement on Schedule 13D with respect to the beneficial ownership of shares of Common Stock of Neuraxis, Inc. is filed jointly on behalf of each of them.

     

     

    Rosalind Advisors, Inc.

    By: _____________________________

    Name: Steven Salamon

    Title: President

     

    Rosalind Master Fund L.P.

    By: _____________________________

    Name: Mike McDonald

    Title: Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)

     

    Steven Salamon

    By: _____________________________

    Name: Steven Salamon

     

     

     

     

    Get the next $NRXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Carrico Brian Allen

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:56 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:53 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferge Kristin A was granted 13,157 shares, increasing direct ownership by 1,112% to 14,340 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:54 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hannasch Brian bought $800,001 worth of shares (355,556 units at $2.25), increasing direct ownership by 46% to 1,131,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    7/3/25 11:24:27 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    4/23/25 4:38:50 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    SEC Filings

    View All

    Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/24/25 8:22:36 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:27:48 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Neuraxis Inc.

    424B5 - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:26:10 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

    Achieves significant expansion of NeurAxis' total addressable marketClearance now includes patients aged "8 years and older"Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated

    10/24/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

    CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 11:00 a.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at

    9/18/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    View All

    NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

    CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

    1/31/24 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $NRXS
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13D filed by Neuraxis Inc.

    SC 13D - Neuraxis, INC (0001933567) (Subject)

    12/2/24 11:53:07 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Neuraxis Inc.

    SC 13G - Neuraxis, INC (0001933567) (Subject)

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    SC 13G/A - Neuraxis, INC (0001933567) (Subject)

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

    CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi

    8/5/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

    CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

    5/12/25 8:15:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care